Estados financieros detallados de Corbus Pharmaceuticals Holdings, Inc. (CRBP): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $7.26, CRBP presenta beneficios negativos (P/E no significativo) y un ROE del -87.05%. La capitalización bursátil es de $135M.
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | $1.9M | $2.4M | $4.8M | $36.1M | $3.9M | $881705 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $15.4M | $26.0M | $48.6M | $89.6M | 0 | $1.6M | $1.5M | 0 | $600000 | 0 |
| Beneficio Bruto | -$13.5M | -$23.6M | -$43.8M | -$53.5M | $3.9M | -$757527 | -$1.5M | 0 | -$600000 | 0 |
| I+D | $15.4M | $26.0M | $48.6M | $89.6M | $98.3M | $36.4M | $16.1M | $31.2M | $32.2M | $70.1M |
| Generales y Administrativos | $6.5M | $9.0M | $13.0M | $23.6M | $28.5M | $20.4M | $18.7M | $13.9M | $16.5M | $15.2M |
| Gastos Operativos | $21.9M | $35.0M | $61.6M | $23.6M | $126.7M | $55.2M | $33.3M | $45.1M | $48.1M | $85.3M |
| Beneficio Operativo | -$20.0M | -$32.6M | -$56.7M | -$77.1M | -$122.8M | -$56.0M | -$34.8M | -$45.1M | -$48.7M | -$85.3M |
| EBITDA | -$19.9M | -$32.3M | -$56.3M | -$76.4M | -$121.1M | -$42.2M | -$38.7M | -$40.1M | -$37.7M | -$78.3M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | $1.0M | $1.8M | $2.1M | $2.9M | $1.9M | 0 |
| Beneficio Antes de Impuestos | -$20.0M | -$32.4M | -$55.7M | -$71.5M | -$111.3M | -$45.6M | -$42.3M | -$44.6M | -$40.2M | -$78.5M |
| Impuestos | $13617 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$20.0M | -$32.4M | -$55.7M | -$71.5M | -$111.3M | -$45.6M | -$55.8M | -$44.6M | -$40.2M | -$78.5M |
| BPA | $-14.58 | $-19.38 | $-29.30 | $-33.55 | $-42.72 | $-11.13 | $-10.15 | $-10.31 | $-3.68 | $-5.90 |
| BPA Diluido | $-14.58 | $-19.38 | $-29.30 | $-33.55 | $-42.72 | $-11.13 | $-10.15 | $-10.31 | $-3.68 | $-5.90 |
| Acciones en Circulación (Diluidas) | $1.4M | $1.7M | $1.9M | $2.1M | $2.6M | $4.1M | $4.2M | $4.3M | $10.9M | $13.3M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | -$49000 | 0 |
| Beneficio Operativo | -$24.4M | -$22.0M | -$24.3M | -$36.2M |
| EBITDA | -$23.3M | -$20.5M | -$22.9M | -$34.4M |
| Beneficio Neto | -$23.3M | -$20.6M | -$23.0M | -$35.0M |
| BPA | $-1.90 | $-1.54 | $-1.23 | $-1.81 |
| BPA Diluido | $-1.90 | $-1.54 | $-1.23 | $-1.81 |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $15.0M | $62.5M | $41.7M | $31.7M | $85.4M | $25.0M | $17.0M | $13.7M | $17.2M | $28.5M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | $72.6M | $42.2M | $7.2M | $131.9M | $134.8M |
| Cuentas por Cobrar | $1.3M | 0 | 0 | $2.7M | $2.6M | 0 | 0 | 0 | 0 | $1.5M |
| Inventario | $0 | 0 | 0 | -$2.7M | $350000 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $17.4M | $65.5M | $44.2M | $38.2M | $92.1M | $100.2M | $60.2M | $23.5M | $153.0M | $167.0M |
| Inmovilizado Material | $435251 | $1.4M | $2.7M | $10.9M | $9.3M | $7.0M | $5.5M | $4.0M | $2.5M | $1.2M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $17.9M | $67.0M | $47.0M | $49.1M | $102.3M | $107.7M | $66.3M | $28.3M | $155.9M | $168.2M |
| Cuentas por Pagar | $3.4M | $3.1M | $6.3M | $11.1M | $7.4M | $1.8M | $2.2M | $3.2M | $4.8M | $2.2M |
| Deuda a Corto | $271757 | $332861 | $394305 | $752659 | $710158 | $3.9M | $3.1M | $16.2M | 0 | 0 |
| Pasivos Corrientes | $8.9M | $8.2M | $18.1M | $34.9M | $31.9M | $17.0M | $12.6M | $31.9M | $11.8M | $20.7M |
| Deuda a Largo | 0 | 0 | 0 | 0 | $18.0M | $15.6M | $16.0M | 0 | 0 | 0 |
| Pasivos Totales | $9.0M | $9.2M | $19.5M | $43.0M | $57.0M | $38.6M | $33.3M | $35.2M | $13.5M | $20.7M |
| Reservas | -$33.3M | -$65.7M | -$121.4M | -$192.8M | -$304.1M | -$349.7M | -$392.1M | -$436.7M | -$476.9M | -$555.4M |
| Patrimonio Neto | $8.9M | $57.8M | $27.5M | $6.2M | $45.3M | $69.1M | $33.0M | -$6.9M | $142.4M | $147.5M |
| Deuda Total | $276389 | $332861 | $394305 | $9.4M | $26.8M | $26.6M | $25.1M | $20.9M | $3.2M | $1.6M |
| Deuda Neta | -$14.7M | -$62.2M | -$41.4M | -$22.3M | -$58.6M | -$71.1M | -$34.1M | -$21000 | -$145.8M | -$162.3M |
| Capital Circulante | $8.5M | $57.3M | $26.2M | $3.3M | $60.2M | $83.2M | $47.5M | -$8.3M | $141.2M | $146.3M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $27.0M | $28.5M | $26.0M | $23.4M |
| Activos Totales | $109.5M | $168.2M | $144.5M | $127.0M |
| Pasivos Totales | $17.4M | $20.7M | $18.1M | $24.7M |
| Patrimonio Neto | $92.1M | $147.5M | $126.3M | $102.2M |
| Deuda Total | $2.0M | $1.6M | $1.2M | $4.3M |
Flujo de Caja (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$20.0M | -$32.4M | -$55.7M | -$71.5M | -$111.3M | -$45.6M | -$42.3M | -$44.60B | -$40.2M | -$78.5M |
| Amortizaciones | $87664 | $255652 | $493938 | $1.2M | $1.7M | $1.6M | $1.5M | $640.6M | -$2.7M | -$1.1M |
| Compensación en Acciones | $3.2M | $5.7M | $7.6M | $12.0M | $12.5M | $9.5M | $5.7M | $3.47B | $6.1M | $6.3M |
| Cambio en Capital Circulante | $3.1M | -$2.2M | $17.0M | $12.5M | -$3.2M | -$15.7M | -$4.0M | $3.07B | -$5.6M | $9.1M |
| Flujo de Caja Operativo | -$13.6M | -$27.8M | -$30.1M | -$45.7M | -$99.7M | -$48.2M | -$37.5M | -$36.10B | -$41.8M | -$64.5M |
| Inversiones (CapEx) | -$353032 | -$707429 | -$2.3M | -$2.7M | -$484487 | -$54172 | -$13449 | 0 | 0 | -$7000 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | $8100 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$13.9M | -$28.5M | -$32.4M | -$48.5M | -$100.2M | -$48.2M | -$37.6M | -$36.10B | -$41.8M | -$64.5M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$15.6M | -$15.9M | -$25.6M | -$29.6M |
| Inversiones (CapEx) | 0 | -$7000 | -$6000 | -$6000 |
| Flujo de Caja Libre | -$15.6M | -$15.9M | -$25.6M | -$29.6M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $1.6M | $1.4M | $1.9M | $1.8M |
Crecimiento y Márgenes (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | +27.7% | +97.6% | +649.5% | -89.1% | -77.6% | -100.0% | | | |
| Crecimiento Beneficio Neto (anual) | | -62.1% | -71.7% | -28.3% | -55.7% | +59.1% | -22.6% | +20.1% | +9.9% | -95.3% |
| Crecimiento BPA (anual) | | -32.9% | -51.2% | -14.5% | -27.3% | +73.9% | +8.8% | -1.6% | +64.3% | -60.3% |
| Cambio en Acciones (anual) | | +22.0% | +13.6% | +12.1% | +22.3% | +57.4% | +1.7% | +3.8% | +152.2% | +22.0% |
| Crecimiento FCF (anual) | | -104.7% | -13.6% | -49.7% | -106.7% | +51.8% | +22.1% | -96019.6% | +99.9% | -54.3% |
| Margen Bruto | -707.6% | -967.1% | -908.1% | -147.9% | 100.0% | -85.9% | | | | |
| Margen Operativo | -1045.6% | -1334.4% | -1176.8% | -213.3% | -3119.2% | -6350.1% | | | | |
| Margen EBITDA | -1041.0% | -1324.0% | -1166.5% | -211.3% | -3076.2% | -4782.9% | | | | |
| Margen Neto | -1046.3% | -1328.6% | -1154.5% | -197.7% | -2826.1% | -5166.4% | | | | |
| Margen FCF | -728.5% | -1168.1% | -671.2% | -134.1% | -2544.2% | -5471.0% | | | | |
| Tasa Impositiva Efectiva | -0.1% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-10.15 | $-17.04 | $-17.04 | $-22.75 | $-38.46 | $-11.77 | $-9.01 | $-8341.98 | $-3.83 | $-4.84 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $1.4M | $1.7M | $1.9M | $2.1M | $2.6M | $4.1M | $4.2M | $4.3M | $10.9M | $13.3M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -87.05% |
| Rentabilidad sobre capital invertido | -100.35% |
| Rentabilidad sobre activos | -80.25% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.04 |
| Ratio corriente | 5.71 |
Ratios Clave (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -17.39 | -10.99 | -5.98 | -4.88 | -0.88 | -1.66 | -0.33 | -0.59 | -3.21 | -1.38 |
| P/VC | 38.97 | 6.17 | 12.09 | 56.66 | 2.16 | 1.10 | 0.42 | -3.78 | 0.90 | 0.73 |
| P/V | 181.86 | 146.00 | 69.03 | 9.65 | 24.81 | 85.93 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | -707.6% | -967.1% | -908.1% | -147.9% | 100.0% | -85.9% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | -1045.6% | -1334.4% | -1176.8% | -213.3% | -3119.2% | -6350.1% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | -1046.3% | -1328.6% | -1154.5% | -197.7% | -2826.1% | -5166.4% | 0.0% | 0.0% | 0.0% | 0.0% |